SuperworthBioNexus Gene Lab profit margin BGLC
Gross, operating and net profit as a share of revenue over the last twelve months, from 2020.
- Net margin, 12 months
- −82.4%
- Operating margin, 12 months
- −81.8%
- Net margin on a year earlier
- −51.7 pts
- Peer median
- 8.6%
Over the twelve months to Jun 30, 2026, BioNexus Gene Lab kept −82.4% of its revenue as net profit, with an operating margin of −81.8% and a gross margin of 12.3%.
Five years earlier its net margin was 3.1%.
The median for 10 healthcare stocks of a similar size is 8.6%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −40.2% | −39.9% | 14.6% |
| FY2024 | −16.8% | −16.5% | 13.6% |
| FY2023 | −26.9% | −26.5% | 13.6% |
| FY2022 | −3.3% | −2.7% | 11.5% |
| FY2021 | 5.6% | 7.9% | 16.7% |
| FY2020 | 9.6% | 11.2% | 15.1% |
| FY2019 | n/a | n/a | 44.0% |
| FY2018 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −82.4% | −51.7 pts | −81.8% | |
| Q1 FY26 | −54.7% | −31.8 pts | −54.4% | |
| Q4 FY25 | −40.2% | −23.4 pts | −39.9% | |
| Q3 FY25 | −24.3% | −14.1 pts | −24.8% | |
| Q2 FY25 | −30.7% | −6.7 pts | −31.2% | |
| Q1 FY25 | −22.9% | +4.4 pts | −22.8% | |
| Q4 FY24 | −16.8% | +10.1 pts | −16.5% | |
| Q3 FY24 | −10.2% | +19.8 pts | −9.7% | |
| Q2 FY24 | −24.0% | −18.6 pts | −22.8% | |
| Q1 FY24 | −27.2% | −22.9 pts | −26.8% | |
| Q4 FY23 | −26.9% | −23.6 pts | −26.5% | |
| Q3 FY23 | −29.9% | −29.0 pts | −28.8% |
Against its peers
Companies in Healthcare nearest BioNexus Gene Lab's size, closest first, today.
| Company | Profit margin |
|---|---|
| BGLCBioNexus Gene Lab | −82.4% |
| OXBROXBRIDGE RE HOLDINGS | 4.7% |
| EDUCEducational Development | 8.6% |
| GTIMGood Times Restaurants | 1.7% |
| MDRRMedalist Diversified | 80.2% |
| BCGBinah Capital | 2.2% |
| VIPVulcan Infrastructure & Power | 1.0% |
| MXCMexco Energy | 23.3% |
| CKXCKX Lands | n/m |
| MSGMMotorsport Games | 16.2% |
| ATCHAtlasClear | 9.8% |
| Peer median | 8.6% |
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on BioNexus Gene Lab
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.